Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its price objective cut by Wells Fargo & Company from $27.00 to $25.00 in a research report report published on Friday,Benzinga reports. They currently have an overweight rating on the medical device company’s stock.
A number of other research firms have also recently issued reports on TNDM. Royal Bank Of Canada restated an “outperform” rating and set a $26.00 target price (down from $30.00) on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Barclays raised Tandem Diabetes Care to a “hold” rating in a research report on Wednesday, October 7th. Mizuho set a $20.00 price objective on shares of Tandem Diabetes Care in a report on Friday. William Blair assumed coverage on Tandem Diabetes Care in a research report on Friday, August 21st. They issued an “outperform” rating on the stock. Finally, UBS Group initiated coverage on shares of Tandem Diabetes Care in a research report on Tuesday, July 28th. They set a “neutral” rating and a $18.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $27.18.
Read Our Latest Analysis on TNDM
Tandem Diabetes Care Stock Performance
Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical device company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.15. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The firm had revenue of $283.69 million during the quarter, compared to analysts’ expectations of $265.85 million. During the same period in the previous year, the business posted ($0.31) earnings per share. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. On average, equities analysts forecast that Tandem Diabetes Care will post -0.66 EPS for the current year.
Insider Activity at Tandem Diabetes Care
In related news, Director Christopher J. Twomey sold 1,700 shares of the company’s stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $19.15, for a total value of $32,555.00. Following the sale, the director owned 24,434 shares in the company, valued at $467,911.10. This represents a 6.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Tandem Diabetes Care
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC raised its holdings in shares of Tandem Diabetes Care by 157.4% in the 2nd quarter. First Light Asset Management LLC now owns 3,383,553 shares of the medical device company’s stock worth $51,058,000 after purchasing an additional 2,068,838 shares during the period. Defilade Capital Management L.P. purchased a new position in Tandem Diabetes Care during the first quarter valued at approximately $14,606,000. Quantinno Capital Management LP grew its position in Tandem Diabetes Care by 123.5% during the first quarter. Quantinno Capital Management LP now owns 653,870 shares of the medical device company’s stock worth $12,535,000 after buying an additional 361,361 shares in the last quarter. First Trust Advisors LP purchased a new stake in Tandem Diabetes Care in the first quarter valued at approximately $6,570,000. Finally, Beaconlight Capital LLC bought a new stake in shares of Tandem Diabetes Care during the 1st quarter worth $4,867,000.
Key Stories Impacting Tandem Diabetes Care
Here are the key news stories impacting Tandem Diabetes Care this week:
- Positive Sentiment: Third-quarter revenue was $283.7 million, up 13.8% year over year and above analyst expectations of $265.85 million. The loss of $0.10 per share was also narrower than the consensus loss of roughly $0.25. Gross margin improved to 57%, up 2.7 percentage points year over year. Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
- Positive Sentiment: Tandem forecast 2026 sales of $1.065 billion to $1.085 billion, providing investors with a full-year revenue outlook. Tandem outlines 2026 sales range as CEO transition is set
- Neutral Sentiment: Jeannette Bankes was named president and CEO, succeeding John Sheridan, who is expected to retire at the end of 2026. The planned handover offers continuity but adds a leadership transition for investors to monitor. Tandem names Jeannette Bankes CEO
- Neutral Sentiment: Analyst actions were mixed: Barclays raised its target from $18 to $20 but kept an Equal Weight rating, while Wells Fargo lowered its target from $27 to $25 and maintained Overweight. Both targets remain above the cited $16.91 share price. Barclays rating information Wells Fargo target revision
- Negative Sentiment: Despite improved results, Tandem remains loss-making, with a negative net margin. Continued losses could limit how much investors reward revenue and margin progress. Tandem reports third-quarter loss
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.
Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.
Featured Articles
- Five stocks we like better than Tandem Diabetes Care
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
